Cognizance Biomarkers announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent providing further protection for its novel neuro-inflammatory biomarkers for the diagnosis, management and treatment of epileptic seizures. This is the second issued patent covering methods for detecting seizures and assessing the effectiveness of treatments for seizures using neuro-inflammatory biomarkers. These patents, which are based on seminal work by Drs. Peter Crino and John Pollard, leading scientists in the field of neuro-inflammation, form the core of Cognizance’s broad intellectual property portfolio.
“This new patent confirms our strategy of working closely with our academic colleagues to expand the patent protection for our novel neuro-inflammatory biomarkers for the diagnosis of epileptic seizures,” said Todd Wallach, President and Chief Executive Officer. “This is an exciting time for our company, as we enlarge our patent estate while also generating new scientific data confirming the validity and utility of our unique diagnostic approach, which has demonstrated the potential to accurately distinguish between actual seizures and seizure-like events. We will be presenting clinical data later this year showing that we can detect whether patients have had a recent seizure by analyzing the modulation of selected neuro-inflammatory biomarkers. Importantly, the presence of potentially confounding inflammatory disease had no impact on the diagnostic accuracy of our approach.”